NCT03443830View on ClinicalTrials.gov

Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

September 12, 2018

Study Completion Date

December 4, 2018

Conditions
Treatment of Acute Zika Virus Infection
Interventions
DRUG

Tyzivumab

Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes

Trial Locations (1)

169608

SingHealth Investigational Medicine Unit, Singapore

All Listed Sponsors
collaborator

Duke-NUS Graduate Medical School

OTHER

collaborator

Singapore Clinical Research Institute

OTHER

collaborator

National University of Singapore

OTHER

collaborator

National University Hospital, Singapore

OTHER

lead

Tychan Pte Ltd.

INDUSTRY

NCT03443830 - Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans | Biotech Hunter | Biotech Hunter